United Kingdom (UK)
Recombinant monoclonal antibody to LAG-3. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Ab8438.
UniProt Accession Number of Target Protein: P18628
Alternative Name(s) of Target: CD223; LAG3; FDC; Lymphocyte activation gene 3 protein
Specificity: The antibody is specific for human LAG-3. The antibody cross-reacts with cynomolgus LAG-3. The antibody does not cross react with murine LAG-3.
Application Notes: The antibody is a humanized version of the mouse antibody mab84c. The humanized antibody could bind to hLAG-3+ cells, with an EC50 value that does not exceed 1.5nM. The humanized antibody prevented the binding activity of human LAG-3 and Daudi cells. The binding affinity of the humanized antibody was measured by surface plasmon resonance (Kd= 0.71 nM). The antibody was employed to design bispecific antibodies against LAG-3 and PD-L1, which antibody retained the binding activity to dual-target LAG3 and PD-1. Further, both the combination of the antibody and PD-1 antibody and the bispecific LAG-3 and PD-L1 antibody showed a good tumour inhibition effect in in vivo application (CN111848794).
Antibody first published in: PMID: